NDAORALCAPSULE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
15
Data completeness
4/8 — Partial
NEREUS (tradipitant) by Vanda Pharmaceuticals. Approved for motion sickness, gastroparesis. First approved in 2025.
Drug data last refreshed Yesterday
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (2)
Clinical Trials (15)
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Started Mar 2026
280 enrolled
Nausea and VomitingObesity
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
Started Feb 2025
124 enrolled
Obesity
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Started Jan 2024
100 enrolled
Idiopathic GastroparesisDiabetic GastroparesisGastroparesis
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Started Sep 2023
316 enrolled
Motion Sickness
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Started Feb 2023
705 enrolled
Motion Sickness
Worked on NEREUS at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.